Question 1

Are bioidentical hormones approved in Canada?

Accepted Answer

Yes, with an important distinction. The individual hormone ingredients used in BHRT (estradiol, estriol, progesterone, testosterone) are all recognized by Health Canada as drug substances, and many are also available as approved finished products: estradiol patches (Estradot, Climara), estradiol gels (Estrogel, Divigel), oral micronized progesterone (Prometrium), vaginal estradiol products, and testosterone preparations. DHEA is treated separately as a Schedule IV controlled substance with one approved finished product (Intrarosa, a vaginal insert); other DHEA forms are compounded. Compounded BHRT is different but not unregulated. Compounded preparations are bespoke formulations of those same regulated ingredients, custom-prepared by a licensed compounding pharmacy based on a prescriber's instructions. Health Canada does not approve each compounded formulation because the possible combinations of dose, ingredients, and base cream run into the millions: approving each one would be impossible and unnecessary. Instead, compounding pharmacies are regulated provincially through the pharmacy colleges (such as the Alberta College of Pharmacy and the Ontario College of Pharmacists) and must follow national standards set by NAPRA, the National Association of Pharmacy Regulatory Authorities. Both pathways are legal. Approved finished products are a standard option for many patients. Compounded preparations are used when there is a clinical reason: a dose not commercially available, a hormone like DHEA in a form not available as a Canadian finished product, or a patient who cannot tolerate ingredients in commercial preparations.

Question 2

Do you need a prescription for BHRT in Canada?

Accepted Answer

Yes. All hormones used in BHRT, whether dispensed as approved finished products or as compounded preparations, are Schedule F (prescription-only) drugs under federal regulation. They cannot legally be sold over the counter or dispensed without a valid prescription from an authorized prescriber. The prescription requirement applies whether you receive a Health Canada-approved product (such as an Estradot patch) from a standard pharmacy or a compounded preparation from a compounding pharmacy. In both cases, the prescribing process is the same: a qualified clinician evaluates your symptoms, medical history, and lab work, and writes a prescription specifying the hormone, dose, and route of administration.

Question 3

Who can prescribe BHRT in Canada?

Accepted Answer

Three types of clinicians can prescribe BHRT in Canada: nurse practitioners (NPs), physicians (MDs), and naturopathic doctors (NDs) in select provinces. Nurse practitioners hold full prescriptive authority for BHRT in every province and territory in Canada under their respective nursing regulators. No physician referral is required to see an NP. Family physicians, gynecologists, and endocrinologists prescribe under their provincial colleges of physicians. Naturopathic doctor prescribing authority for BHRT is more limited. In Alberta, NDs hold no pharmaceutical prescribing authority and cannot prescribe pharmaceutical-grade estradiol, progesterone, or testosterone. In British Columbia and Ontario, NDs who have completed additional certification (CONO certification in Ontario) hold limited prescribing authority for hormone health: bioidentical estrogen and progesterone in topical or suppository form only. Oral, injectable, and patch forms remain outside their scope, as does testosterone (a controlled substance, which NDs cannot prescribe in any province). In Saskatchewan, Manitoba, and the Atlantic provinces, ND prescribing authority is either absent or very limited. One regulatory point worth understanding: the Canada Health Act covers publicly insured services delivered through provincial health plans, which generally means physician visits. Consultation-based BHRT care, especially when delivered by NPs or NDs in a private clinic setting, typically falls outside provincial coverage even though the clinicians and prescriptions are fully regulated. This is why most menopause-focused BHRT clinics operate on a fee-for-service model. At Red Leaf Wellness, both our NP team and our naturopathic team practice in jurisdictions where they hold authority, and no referral is needed to book.

Question 4

How much does BHRT cost in Canada?

Accepted Answer

BHRT cost in Canada has two components: consultations and medications. The two are billed and covered differently. Initial consultations with private menopause-focused clinics typically range from $200 to $450 depending on the prescriber and the depth of assessment. Follow-up appointments are usually shorter and lower-cost. Most consultation fees fall outside provincial health coverage because the Canada Health Act does not extend to NP, ND, or counselling services delivered in a private clinic setting. Medication costs vary by formulation. Health Canada-approved bioidentical products (estradiol patches, micronized progesterone, estradiol gel) typically run $30 to $90 per month and are usually covered like any other prescription by private extended health plans. Compounded BHRT regimens typically run $60 to $200 per month depending on the formulation and the compounding pharmacy. Many patients reduce out-of-pocket costs by using extended health benefits, Health Spending Accounts, or by working with their family physician to renew prescriptions once a stable regimen is established. Provincial drug plans cover approved products for eligible patients (seniors, low-income residents) under their formulary rules.

Question 5

Is BHRT covered by insurance in Canada?

Accepted Answer

Coverage depends on what is being billed and your insurance plan. Three sources of coverage are worth understanding: Provincial health plans (Alberta Health, OHIP, MSP, and others) cover services within the scope of the Canada Health Act, which generally means publicly insured physician visits and hospital-based care. Consultation-based BHRT care delivered through NPs, NDs, or counselling in a private clinic setting falls outside this scope and is not covered. Provincial drug plans cover certain approved bioidentical products (such as estradiol patches and Prometrium) for eligible patients under their formulary rules. Private extended health benefit plans (provided by Sun Life, Manulife, Canada Life, Blue Cross, and others) often cover a portion of NP, ND, or counselling consultation fees, and most cover Health Canada-approved bioidentical prescription medications the same way they cover any prescription. Coverage of compounded BHRT varies by plan: some plans cover it fully, some partially, some not at all. Health Spending Accounts and Personal Spending Accounts can typically be used for both consultation fees and medications, including compounded preparations that may not be reimbursed under traditional benefits. Confirm specific coverage with your insurance provider before your first appointment.

Question 6

What is the difference between BHRT and traditional HRT?

Accepted Answer

The terms refer to two different things: the molecular structure of the hormones used, and the regulatory pathway through which they are prescribed. Traditional HRT historically meant hormone preparations that are not chemically identical to human hormones. The most well-known example is Premarin (conjugated equine estrogens), which is derived from pregnant mare urine and contains a mix of estrogens including estrone sulfate that are different in structure from human estradiol. The progestin commonly paired with Premarin, medroxyprogesterone acetate (MPA, sold as Provera), is a synthetic progestin that binds progesterone receptors but also activates other receptors and has a different metabolic profile from human progesterone. Most of the increased breast cancer signal in the original Women's Health Initiative study was driven by combined Premarin-plus-Provera therapy, not by bioidentical regimens. BHRT uses hormones that are chemically identical to those your body produces: 17-beta-estradiol, micronized progesterone, and testosterone. These molecules bind the same receptors as your natural hormones and follow the same metabolic pathways. In Canada today, the standard of care for most patients starting hormone therapy is a Health Canada-approved bioidentical regimen, typically a transdermal estradiol patch or gel combined with oral micronized progesterone (Prometrium) when a progestogen is needed for endometrial protection. The practical takeaway: the older synthetic-versus-bioidentical debate has largely resolved in favour of bioidentical hormones at the molecular level, and the 2022 Menopause Society position statement reflects this. The remaining distinction in Canada is between approved finished bioidentical products and compounded bioidentical preparations, not between bioidentical and synthetic.

Question 7

Did the FDA really remove the black box warning from hormone therapy?

Accepted Answer

Yes. On November 10, 2025, the FDA and U.S. Department of Health and Human Services announced they would initiate removal of the black box warning on estrogen-containing hormone therapy products. On February 12, 2026, the FDA approved the first six product label changes, removing warnings about cardiovascular disease, breast cancer, and probable dementia from products including Prometrium, Divigel, Bijuva, Cenestin, Enjuvia, and Estring. Twenty-nine drug companies are updating their hormone therapy labels. In Canada, Health Canada has not yet issued identical labelling changes, but the Canadian Menopause Society publicly welcomed the FDA decision and is engaging with Health Canada to align Canadian labelling with current evidence. The change applies to Health Canada-approved bioidentical products only, not to compounded BHRT. The endometrial cancer warning remains on systemic estrogen-alone therapies for women with an intact uterus.

Question 8

Who should not take BHRT?

Accepted Answer

BHRT is not appropriate for everyone. Standard contraindications to systemic hormone therapy include a personal history of hormone-sensitive cancers (breast, ovarian, endometrial), a history of venous thromboembolism (deep vein thrombosis, pulmonary embolism), active liver disease, untreated coronary artery disease, recent stroke, or undiagnosed vaginal bleeding. Pregnancy and breastfeeding are also contraindications. Several of these situations carry more nuance than the standard list suggests. Local vaginal estrogen for genitourinary symptoms uses very low doses with minimal systemic absorption and has a much more favourable safety profile than systemic therapy: it can sometimes be appropriate even for women with a history of certain breast cancers, in consultation with their oncology team. Personal vs family history of blood clots is treated differently. Transdermal estrogen (patches, gels) does not carry the clotting risk that oral estrogen does, which broadens the patient population who can safely use estrogen therapy. The general principle: contraindications are starting points for a clinical conversation, not absolute rules. A qualified prescriber can help assess your individual situation and identify which BHRT options, if any, are appropriate for you. Some patients who screen out of systemic therapy still benefit from local vaginal estrogen or from non-hormonal alternatives like fezolinetant.

Question 9

How long does it take for BHRT to work?

Accepted Answer

Most patients begin noticing symptom improvement within 2 to 4 weeks of starting an appropriate BHRT regimen, with full benefits typically established by 8 to 12 weeks. Vasomotor symptoms (hot flashes, night sweats) often improve first. Sleep, mood, and energy levels generally follow. Genitourinary symptoms (vaginal dryness, urinary urgency) often take longer, sometimes 8 to 12 weeks of local vaginal estrogen for full effect. Dose adjustments during the first 3 to 6 months are common and expected. Hormone therapy is rarely set-and-forget in the first year. Your prescriber should be reviewing your response and adjusting the regimen as needed.

Question 10

At what age should you stop taking BHRT?

Accepted Answer

There is no fixed age at which BHRT must be stopped. Neither the 2022 Menopause Society position statement nor SOGC Guideline No. 422a endorses a hard upper age limit. The decision to continue or stop should be based on the individual's symptom burden, personal risk profile, and overall health, reassessed with their prescriber on an ongoing basis. The general guidance is that starting hormone therapy under 60 or within 10 years of menopause onset has the most favourable benefit-to-risk profile. This is sometimes called the timing hypothesis, and it is supported by reanalysis of the WHI data by age cohort, the KEEPS trial, and the ELITE trial. Continuing therapy beyond that window can be appropriate for individuals whose symptoms persist or who benefit from ongoing bone protection, as long as the risk profile remains favourable. Many women continue BHRT into their 60s and beyond under appropriate clinical supervision, particularly using transdermal delivery (which avoids the clotting risk associated with oral estrogen). Stopping abruptly often causes symptoms to return, sometimes severely, so any discontinuation should be planned in consultation with your prescriber rather than done unilaterally.

Question	Health Canada-authorized prescription product	Compounded preparation
What is it?	A finished prescription medicine authorized for sale in Canada, with a product-specific DIN and approved labelling.	A customized medicine prepared by a compounding pharmacy for an individual prescription.
Is the finished product reviewed by Health Canada before sale?	Yes. Health Canada reviews quality, safety and efficacy evidence for the product and its proposed use.	The individual compounded preparation is not reviewed and authorized as a finished product in the same way.
Why might it be discussed?	A prescriber may consider an authorized option based on symptoms, health history, preferences and treatment goals.	A prescriber may consider compounding when there is a specific need that cannot be met by an available authorized product. The reason should be clear and individualized.
Does “bioidentical” settle which is safer or works better?	No. The molecule’s structure is only one consideration; route, dose, risks and evidence matter.	No. A customized form is not automatically safer or more effective.

BHRT in Canada: Products, Costs, Coverage and Access

Key takeaways

What does BHRT mean in Canada?

Approved hormone medicines and compounded preparations

What can hormone therapy help with?

How do you access BHRT in Canada?

What does BHRT cost in Canada, and is it covered?

Related questions

Frequently asked questions

Are bioidentical hormones approved in Canada?

Does insurance cover BHRT in Canada?

Is compounded BHRT safer or more effective?

Bring balance into your life. Choose a healthier and happier lifestyle.

Restore+ Hormone Health Self-Assessment

About You

Estrogen

Progesterone

Thyroid

Androgens (Testosterone & DHEA)

Cortisol

Get your Results!